RP2 and RP3 are versions of RP1 which additionally express an antibody-like molecule against CTLA-4 or the anti-CTLA-4 molecule together with optimized immune co-stimulatory pathway ligands. This provides targeted delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, rather than systemic exposure through systemic antibody-base approaches.